About US
Contact us
-
Bayer wins new use for fast-moving cancer drug StivargaBayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric can2013/2/27
-
Definiens Appoints Professor Dr. Ralf Huss as Chief Medical OfficerDefiniens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced the appointment of renowned surgical and anatomical pathologist Dr. Ralf Huss as2013/2/27
-
Ranbaxy back in gear for generic Lipitor productionRanbaxy Laboratories is back in the generic Lipitor saddle again. Three months after stopping production of the cholesterol fighter and recalling almost a half-million bottles, the Indian drugmaker s2013/2/26
-
Pfizer eyes more Chinese partners to speed growthEveryone in pharma wants a piece of China. In spite of recent price cuts, China remains one of the fastest-growing drug markets in the world. The question is, what piece? And how can it be had? Appar2013/2/26
-
Roche produces 'hidden billionaires' as cancer drugs dominateRoche ($RHHBY) shares quickly ticked up today after the FDA approved its highly anticipated breast treatment Kadcyla. That will only add to the wealth of a dozen shareholders tied to the families tha2013/2/25
-
Affymax, Takeda pull Omontys after fatal allergic reactionsSevere hypersensitivity reactions in Omontys patients prompted Affymax ($AFFY) and Takeda Pharmaceutical to recall all lots of the anemia drug, designed for use in dialysis patients. Some of the reac2013/2/25
-
ILE Pharmaceutical Materials Co. sincerely invites you to visit CPhI South East Asia 2013ILE Pharmaceutical Materials Co. sincerely invites you to visit CPhI South East Asia 2013Date: 20 – 22 March, 2013Address: Jakarta International Expo – Kemayoran, Indonesia ILE Stand No.: JCA01 (CC2013/2/22
-
German cost agency spurns Xalkori, KomboglyzeThe well-armed German pricing gatekeepers have dismissed two more Big Pharma drugs. Pfizer's ($PFE) lung cancer treatment Xalkori and the Bristol-Myers Squibb ($BMY)/AstraZeneca ($AZN) diabetes drug2013/2/22
-
Lyrica matches UCB drug in Pfizer's latest epilepsy trialPfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilep2013/2/22
-
Pfizer demands rehearing in generic Reglan casePfizer ($PFE) asked the Alabama Supreme Court to think twice before allowing generics patients to sue branded drugmakers. The company filed for a rehearing yesterday, after the state's top court det2013/2/20